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ABSTRACT 
Multiple sclerosis (MS) is a chronic disease in which both genetic and environmental 
risk factors contribute to disease susceptibility. MS patients suffer from inflammatory 
lesions in the central nervous system which results in demyelination of nerve cells, 
reduced neuronal activity and finally neurodegeneration. The immune system has a 
central role in MS pathogenesis and human leukocyte antigen (HLA) molecules are key 
players. The genes encoding HLA class I and II molecules are highly polymorphic 
isotypically and allotypically which makes it problematic to identify which variants 
affect disease susceptibility.  
 
The strongest genetic risk factor for MS is a haplotype of HLA class II alleles, 
DRB1*15:01,DRB5*01:01,DQA1*01:02,DQB1*06:02 (below referred to as 
DRB1*15) which increases the risk of MS 3-fold compared with the general Swedish 
population where the lifetime risk of MS is 0.2%. Our group pioneered the 
identification of a protective effect of the HLA class I region, by discovering that HLA-
A*02 decreases the risk of MS by 40%. The main focus in this thesis has been to 
identify additional HLA factors, if any, that influence MS susceptibility. 
 
In papers I and II we genotyped 1,784 Swedish and Norwegian MS patients and 1,660 
controls, for HLA-DRB1, HLA-A, HLA-C, and eventually also HLA-B, and applied 
several statistical methods, mainly logistic regression analyses. We conclude that, in 
addition to the roles played by DRB1*15 and HLA-A*02, additional influence on 
susceptibility is exerted by HLA-DRB1*01, HLA-DRB1*07 and HLA-B*12, which are 
negatively associated with MS and HLA-B*14 which increases the risk of MS. Analysis 
based on haplotypes, rather than on alleles, showed that a haplotype carrying HLA-
A*02, HLA-C*05 and HLA-B*12 is markedly protective, reducing the risk of MS 2.4-
fold, also outweighing the risk of HLA-DRB1*15 when present on the same haplotype.  
 
Paper III focuses on a possible interaction between genetic background (DRB1*15) 
and an environmental influence, a month-of-birth effect on MS risk. We demonstrate 
that patients born in April have a higher risk of being DRB1*15 positive. On the 
contrary, patients born in November have a lower risk of being DRB1*15 positive.  We 
hypothesize that pregnancies exposed to a lower degree of sunlight thus lower levels of 
Vitamin D, confer an increased risk for a DRB1*15 positive child to later develop MS. 
  
In paper IV the influence of HLA genes on the risk of developing neutralizing 
antibodies (NAbs) to interferon beta (IFN-β) treatment was studied. We show that the 
risk allele for MS, HLA-DRB1*15, is also a risk factor for development of NAbs in 
patients treated with high dose subcutaneously administered IFN-β 1-a, but not for IFN-
β 1-b. DRB1*15 is also a risk factor for developing antibody titers high enough to 
abolish the effect of treatment. Thus, the genetic risk of NAbs varies with IFN-β 
formulation. 
 
This thesis adds several pieces of information to the large MS genetics puzzle and 
suggests several roles of HLA genes and molecules that should be further investigated. 
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1 GENETIC VARIATIONS OF IMPORTANCE IN THIS 
THESIS 
 
To study genetic variations associated with complex disease, it is important to 
understand its definitions and origins. Here, I will give a brief introduction to how 
variations in the human genome arise, how it spreads in a population and why it is 
important. This is only a short overview and there are exceptions to the examples 
presented as well as more complicated underlying mechanisms that I have chosen to 
not discuss here.  
 
1.1 INTRODUCTION TO GENETIC VARIATION 
When the embryo is formed it has two copies of the human DNA, one from the 
maternal side and one from the paternal side. Each copy consists of 23 chromosomes 
and the two homologous setups are basically the same (I here disregard the difference 
between the X and Y chromosomes, since it does not matter in this respect) although 
there are small differences between them. One base here and there is different while all 
the surrounding bases are the same between two homologous chromosomes. The 
human genome normally has five corner stone bases, adenine (A), cytosine (C), 
guanine (G), thymidine (T) and urasil (U) in which T is specific to DNA and U to 
RNA. 
 
Mutation is the term used when a sudden change is introduced in the genome. 
Mutations can arise from several sources of which errors in DNA replication is one that 
is self-inflicted, irradiation and viruses are two extraneous sources out of many. DNA 
replication occurs when a cell prepares for division, e.g. in the developing embryo or 
when new skin cells are formed. As the cells start to divide in the new individual, more 
and more mutations arise in the DNA. If the mutations arise in cells that later produce 
germline cells they will have a chance to be carried on to the next generation. There are 
cellular mechanisms that identify and correct mutations in the replication process, and 
cells that do not function correctly are normally eliminated. 
 
Some parts in the genome are more prone to vary than others. Regions where mutations 
frequently arise are called “mutation hotspots”, and so called “conserved regions” tend 
to have lower mutation rates. Conserved regions are very similar between species and 
does often contain some kind of evolutionary important segment that was not beneficial 
for the individual if altered. This process of non-selection is sometimes referred to as 
“purifying selection”, and this process keeps new mutations in this region on a low 
level in the species. 
 
It is important to distinguish the difference between an individual’s DNA and the DNA 
in the population i.e. all individuals taken together. One specific individual has only 
two copies of DNA which is then altered within each cell during its lifetime. This 
results in a mosaicism within the body although the frequency of each mutation is very 
low, most probably only present in one or very few cells. All these mutations disappear 
with us when we die unless some were present in a germline cell resulting in a child. 
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Then the mutations will be present in all cells of the child. This child will have a 
chromosome from one parent that have one set of mutations and one from the other 
where other mutations are present. Therefore, when this individual in itself has a child, 
there will be a 50% chance that the paternal mutations are carried on to the next 
generation, and 50% for the maternal mutations at a specific location in the genome. By 
these means, the chance of spreading the mutations through the generations alters the 
proportion of the population that has the mutation over time. This random event of a 
mutation being carried on to the next generation is called genetic drift. DNA carried on 
to the next generation is a sample of the former generation and can thereby alter the 
population frequency of every base pair in the DNA.  
 
If a mutation of a specific base becomes common in the population it is called a single 
nucleotide polymorphism (SNP). A SNP is defined as a variation in the population at a 
specific base pair position with a minor allele frequency of more than 1%. SNPs are 
generated over time by mutation of the ancestral allele, which is the original allele in 
the former generations. The SNP is said to have two or more alleles (variants, e.g. A 
and G) of which one is the ancestral allele and the others are the new alleles. Normally 
only one alteration of the ancestral allele is present in the population but there are SNPs 
with three or even four alleles.  
 
There are several factors that may increase the frequency of an allele in the population. 
Migration of individuals is one such event. Migration is seldom random, usually whole 
families or closely related individuals move together, thereby increasing the allele 
frequency of the variants they harbor into the new population. Another event is when a 
new pathogen strikes a population. If a specific variant of DNA is less beneficial for 
survival, this allele will decrease in frequency in the population. If there is a selective 
advantage for a specific allele, this will increase in frequency within the population.  
These two types of narrowing the allelic diversity of a population are often referred to 
as a “genetic bottleneck”.  
 
Genes are built up mainly by introns and exons and several other elements, such as 
promoters. Introns and exons are both transcribed but only exons form the spliced 
mRNA that translates into a protein. Promoters are the starting sequences for the 
transcription and are situated in front of the genes. The transcription complex 
assembles at the promoters upon transcription. The RNA that is formed is then 
processed in various ways and forms the mRNA which is either functional in itself or is 
used as a blueprint of a protein. The ribosome assembles the protein by joining amino 
acids according to the mRNA blueprint. The process of transcription of DNA into RNA 
and translation of RNA into protein is tightly regulated on all levels. There are signals 
within the cell that induce or silence transcription, ways of regulating the amount of 
RNA, and pathways to degrade mRNAs and proteins fast or even protect the protein 
from degradation. We all carry multiple new mutations, but only a small fraction cause 
any detectable phenotype.  
 
Most of the genome does not encode for genes, it also contain so called “gene deserts” 
that we have so far not understood the function of. These deserts are long stretches of 
DNA that do not seem to contain any genes that we know of. There are only about 
23,000 genes in the human genome and only ~2% of the genome is used for coding 
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sequences [1, 2]. Some of the former gene deserts have been found to contain long 
range regulatory elements for genes, microRNAs regulating protein expression or long-
coding RNAs (lincRNAs) which lack any known function.  
 
Population admixture, migrations, genetic drift and selection formed the human genetic 
landscape of today and with molecular techniques one can study the similarities and 
differences between populations and investigate how genetically related different 
populations are [3].  
 
In an individual, by using any of a number of genotyping techniques, one can establish 
exactly which base (A, C, G or T) the individual has at a specific base pair position in 
his or her genome. The combination of these two alleles on the two homologous 
chromosomes is the individuals´ genotype at that position. If the same base is present 
on both chromosomes the individual is said to be homozygous at that position. If they 
differ the individual is heterozygous.  
 
In summary, a human body contains a lot of variation, but these variations rarely have 
any impact on cell function. When drawing a blood sample, it contains many cells thus 
giving a mix of DNA from them all. When genotyping or sequencing the sample, the 
bulk DNA sequence which is the “original” setup inherited from the parents is 
obtained. One base change here and there not inherited from the parents is not 
detectable with the common standard methods of today. 
 
 
1.1.1 Definitions of concepts in genetics 
1.1.1.1 Knowing the phase, owning the phase 
The human chromosome is a stretch of DNA containing a part of the human genetic 
code. The human species has 23 chromosome pairs that contain all the human genes 
(the X and Y chromosomes count as one chromosome pair but they contain different 
genes to some extent). Most cells have two sets of the genetic code and every gene is 
present in two copies, although sometimes only one of them is active, sometimes both 
of them and sometimes none (depends e.g. on tissue, activation and silencing, 
chromatin remodeling and imprinting). The chromosome is made up by base pairs that 
are connected with each other in a long chain (syntenic bases), and the bases come in a 
specific order but with variations which the 1,000 Genomes Project is trying to 
establish (http://www.1000genomes.org/). Having information on the consecutive 
sequence of bases on the same chromosome is called “knowing the phase” and is a very 
desirable knowledge (Example A and B). In case control cohorts one can only estimate 
the phase and until we get single strand sequencing, which is under development, we 
are unable to separate the two homologous chromosomes within one individual.  
 
Example A. When sequencing the individual shown below (individual a/b) one would 
get the genotype G/C on position 8 and T/A on position 18, and all other bases would 
be homozygous. One cannot establish if G at position 8 and T at position 18 are on the 
same chromosome or if G and A at these positions are on the same chromosome with 
common methods. 
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Chromosome 1a: ACTGGTTGAAGTCAGGGTCCTGAGTC 
 Chromosome 1b: ACTGGTTCAAGTCAGGGACCTGAGTC 
 Sequencing gives: ACTGGTT(G/C)AAGTCAGGG(T/A)CCTGAGTC 
Example B. A new variation appears on position 23 where individual a/b was 
homozygous for A when sequencing another individual. Variation at position 18 is 
absent in individual c/d. 
 Chromosome 1c: ACTGGTTGAAGTCAGGGTCCTGAGTC 
 Chromosome 1d: ACTGGTTCAAGTCAGGGTCCTGGGTC 
 Sequencing gives: ACTGGTT(G/C)AAGTCAGGGTCCTG(A/G)GTC 
 
1.1.1.2 Haplotypes 
In example A and B, there are three haplotypes present. A haplotype is a defined stretch 
of a chromosome. In this case there is information on each base but you can shorten the 
haplotypes to only the bases that vary. 
Chromosome 1a: ACTGGTTGAAGTCAGGGTCCTGAGTC or short: GTA 
Chromosome 1b: ACTGGTTCAAGTCAGGGACCTGAGTC or short: CAA 
Chromosome 1d: ACTGGTTCAAGTCAGGGTCCTGGGTC or short: CTG 
 
In families one can use the pedigrees to establish what the haplotypes in the children 
must look like, especially when multi allelic markers are present. In case-control 
settings there are several algorithms available for estimation of haplotypes such as the 
EM-algorithm [4] implemented in the software Haploview or the quasi-Newton 
algorithm [5] implemented in the software UNPHASED. 
 
1.1.1.3 Linkage equilibrium and disequilibrium 
During the human evolution there have been recombinations between chromosomes 
that cause the variations in the genome to mix. Recombination occurs when a germ line 
chromosome is divided and joined with another divided chromosome. Most often it is 
the homologous chromosome inherited from the other parent but sometimes the 
chromosome is joined with a different type of chromosome and this can potentially 
rupture gene functions or induce trisomy (cause of e.g. Down syndrome). 
 
If the alleles of two different SNPs are found together on the same haplotype (i.e. on 
the same chromosome) as often as expected (based on their allele frequencies) those 
alleles are said to be in linkage equilibrium. If, however, the alleles are found either 
more often or more seldom than expected, linkage disequilibrium (LD) is present for 
these markers. New mutations occur on the ancestral haplotype and are in LD with the 
other variants on this haplotype. SNPs close to each other are more likely to be in LD 
compared to SNPs further apart, although the amount of variability makes it impossible 
to assume that neighbor SNPs are in LD. Variants may also be located in a conserved 
region (also called conserved synteny) where recombination does not occur often due 
to, for example, steric hindrance or protecting factors inhibiting recombination. The 
degree of LD can be calculated based on the frequency of markers and genotypes and 
there are two measurements, D´ and r2, that I have used in the thesis papers. They are 
calculated with the help of the disequilibrium coefficient D [6]. 
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D = Pr(AB) – Pr(A) * Pr(B) 
Where Pr(AB) is the proportion of AB haplotypes, that is the frequency of AB 
haplotypes. Pr(A) is the frequency of the A allele on SNP1 and Pr(B) is the frequency of 
the B allele on SNP2. The disequilibrium coefficient can take values between -0.25 and 
+0.25, 0 meaning that the proportion of AB haplotypes equals the expected value 
derived from the allele frequencies.  
  
With the help of D one can calculate the total correlation between two markers in the 
genome.  
r2 = D / {Pr(A)[1-Pr(A)] * Pr(B)[1-Pr(B)]} 
r2 can take values between 0 and 1, where 0 means no association correlation between 
the markers, and 1 means total association correlation. 
 
Lewontin´s D´ is derived from D and is corrected for the maximum value that D can 
take given the allele frequencies. D´ can vary between -1 and 1. 
 
1.2 PATIENT AND CONTROL COHORTS 
Several cohorts have been used in this thesis, collected in Sweden, Norway and 
Canada. There is a balance in reducing power (power is the probability of rejecting a 
null hypothesis when it is false) of a study by mixing populations and introduce 
heterogeneity, but at the same time increase power by increasing the numbers of 
individuals studied. To avoid reduction of power, the populations should be as similar 
as possible. Even though I did not detect any significant differences between the 
Norwegian samples and the Swedish samples I chose to include “country of origin” in 
the logistic regression models in paper I and II just in case some hidden pattern could 
be present underneath the allele frequency distribution. 
 
In paper III where Canadian, Norwegian and Swedish samples were included, we only 
analyzed carriage of one human leukocyte antigen (HLA) allele and the frequency was 
similar between the countries.  
 
1.2.1 Study design 
In the four articles included in this thesis, case control design was used in three and a 
case-only design in the fourth.  
 
1.2.1.1 Cohort study design, why do we not use this? 
Case control design is commonly used when studying diseases that are not so common 
in the population. The “opposite” of case control studies are cohort studies where you 
take a random sample of the population and study the number of individuals that 
develop disease over some period of time [7]. This is not very effective in a rare disease 
since large samples are required to reach a sufficient number of cases. It can answer 
several interesting questions such as how many individuals in the population develop 
disease and at which rate this is happening. But when studying how genetics is 
involved in the development of disease the number of cases in such a study will be too 
few to get a reliable result even though the prevalence of MS in Sweden is 188.9 per 
100,000 individuals [8]. It would require a starting cohort of around 20 million people 
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to obtain 1000 MS cases after 1 year or 4 million people followed for 5 years since the 
incidence in Sweden is about 5 MS cases /100,000 individuals per year. 
 
1.2.1.2 Case control design 
A more effective approach when wanting to study genetic influence in a less common 
disease such as MS is the case control study design where patients are ascertained 
through clinics to participate in the study. To be able to study the effect a certain 
genetic variant has on susceptibility of disease, a comparison between patients and 
individuals that do not have disease must be made. Hence, a group of healthy 
individuals are collected and these are called the “controls”.  
 
1.2.1.3 Case only design 
Sometimes the variable of interest is not measurable in controls, e.g. disease 
progression or response to treatment. The fourth article in this thesis have a case only 
design where we studied the outcome of neutralizing antibodies (NAbs) in interferon 
beta (IFN-β ) treated patients and if HLA variants had any effect on NAb development.  
 
1.3 METHODS OF ANALYZING THE DATA 
1.3.1 Odds Ratio 
Odds Ratio (OR) is a measurement where the odds of being exposed for a variable, for 
example having a specific genetic variant, among patients is divided by the odds of 
being exposed to the same genetic variant in the healthy individuals. The formula looks 
like this, (DRB1*15 is a genetic risk variant for MS): 
 
OR= Odds among patients/Odds among healthy 
Odds among patients = Ncase(DRB1*15 positive)/ Ncase(DRB1*15 negative) 
Odds among healthy = Nctrl(DRB1*15 positive)/ Nctrl(DRB1*15 negative) 
 
Odds ratio is used to describe how the odds of exposure for patients is related to the 
odds of exposure within the healthy individuals. An OR of 1 means that the odds of 
exposure among patients are equal to the odds of exposure among healthy individuals,  
and this is interpreted as that the exposure have no effect on disease susceptibility. A 
higher value indicates a higher odds among patients (risk variable) and a value lower 
than 1 indicate a decrease of exposure in patients compared to healthy individuals 
(protective variable). 
 
1.3.2 Null hypothesis, power and significance of a test statistic 
A scientific hypothesis is a proposed explanation to a certain observation, a relationship 
between variables that results in the outcome. Scientific hypotheses are translated into 
statistical hypotheses that can be tested. A null hypothesis normally states that there is 
no relationship between the variable and the observed outcome. Based on acceptance or 
rejection of the null hypothesis the corresponding scientific hypothesis is either 
supported or not. 
 
Power is the probability to reject a null hypothesis when it is truly false, i.e. the 
sensitivity of a statistical test. Power assessment is most effective when designing a 
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study to see how many patients and controls should be collected in order to evaluate a 
previously reported or a biologically relevant effect of a variable. It can also be used to 
estimate a variables maximum effect size that can be detected in a sample of a certain 
size. 
 
A P-value is a measurement of how likely it is that the observed result or a more 
extreme one would occur by chance if the null hypothesis is true. The significance level 
(αሻ is the cut-off chosen for the P-value in order to denote the result “statistically 
significant”. A significance level of 0.05 is commonly used and a statistically 
significant result would then imply 5% risk or less of committing a type I error i.e. of 
rejecting a null hypothesis that in fact is true. 
 
 8 
2 HUMAN LEUKOCYTE ANTIGEN  
 
2.1 HLA MOLECULES  
Within all vertebrates there is a genomic region encoding immune molecules called the 
major histocompatibility complex (MHC). Many of the immune molecules encoded in 
the MHC have a central role in the immune system when it comes to antigen 
presentation. In humans the antigen presenting molecules are called human leukocyte 
antigen molecules and can display a peptide within their binding clefts that other 
immune cells can either recognize or ignore depending on their education in the thymus 
during their maturation. One can say that the HLA molecules act as a store window that 
you (resembling a T-cell) pass on the street. If it presents something that does not suit 
you, or that you are not interested in, you just pass on by, and thereby ignoring it (self-
molecules). If it presents something you recognize as not appropriate or something 
unusual that makes you have a closer look you will decide if you should react by your 
favorite mechanism, for example protesting on the street (alerting the rest of the 
immune system, T-helper cell) or kill the store owner (cytotoxic T-cell or NK-T-cell) or 
just ignore it (tolerance). However, sometimes the cells protest even if there is nothing 
a normal immune cell would call strange in the store window, that’s when 
autoimmunity is born. T-cells start to react towards self-molecules that should not 
evoke such a reaction. There are several mechanisms behind this type of misbehavior 
and one model is epitope spreading. If using my former example, epitope spreading can 
easily be explained in the following way: suppose there is a new large expansion of 
some store that show a lot of naked skin (antigenic peptides) in their windows, the 
crowd (immune system) gets upset and starts to react by forcing the stores to shut down 
and people (immune cells) participate in raids on the streets (one could only imagine 
what happens within those four walls!). After a while most of those stores are gone, out 
of business (infection is over and taken care of), but the crowd (T-cells) is still upset 
and reacts also on stores that have mannequins in lingerie because it makes them 
remember the almost naked people they just vanquished from the streets. They can also 
react to all the debris left from the riots, the tissue damage itself can activate immune 
response. Although the mannequins were tolerated and considered harmless before the 
invasion they are now considered harmful for society (non-self). This reaction can be 
triggered long after the first infection is gone as long as there are T-cell clones from last 
infection left in the system. This, so called long-term memory of antigens is also one of 
the strengths within the immune system. The next time the same pathogen peptide 
appears on the HLA molecule, the cells will react much faster than last time. 
 
The human MHC gene region, i.e. the HLA gene complex, is located on the short arm 
of chromosome 6 and spans over 7.6 Mb (Megabases). The region is divided into three 
compartments called class I, class II and class III (Figure 1). I will not discuss class III 
much in this thesis since it does not contain any of the classical HLA genes in focus of 
these studies. The class III gene region is situated in-between class I and class II and 
harbors many genes of which a majority are important in immune response.  
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Figure 1. Schematic map over the HLA region on chromosome 6. The centromere is 
located towards the middle of the chromosome and the telomere at the ends. HLA gene 
names are shortened in the figure. 
 
Both class I and class II HLA molecules present peptides to immune cells from the cell 
surface but there are some differences between them that will be briefly discussed in 
the next section. 
 
2.1.1 Class I molecules 
Each class I molecule consists of two peptide chains of which one is the invariant β-2-
microgobulin (β2m), also called the light chain, encoded on chromosome 15. The other 
peptide chain, the heavy chain, is polymorphic and encoded by the genes HLA-A, HLA-
B and HLA-C. Class I genes are expressed in all nucleated cell types. The expression of 
HLA-C is not as abundant as that of HLA-A or HLA-B. It has been described that the 
HLA-C heavy chain poorly associates with β2m [9] resulting in low expression on the 
cell surface.  
 
The HLA class I molecules are assembled by association of the heavy and light chains 
and stabilized by the binding of a peptide in the binding cleft formed within the heavy 
chain. When there is not yet a peptide in the peptide binding groove, the molecule is 
chaperoned by other proteins (called the peptide loading complex, PLC) until a suitable 
peptide can bind [10]. The HLA class I molecule is loaded in the endoplasmic 
reticulum with a 8-9 amino acids long peptide and transported to the surface. These 
peptides are usually formed by degradation of endogenous molecules by the 
proteasome. Most peptides presented in this way are self-peptides, parts of degraded 
proteins produced within the cell, but not all peptides found on HLA class I are coded 
for within the genome. Proteases can cut and paste peptides into variants not normally 
present in a cell [11]. The class I molecules are especially important when a virus 
invades a cell and starts replicating within it. Then HLA class I molecules will present 
virus peptides (non-self) on the surface of the infected cell and alert the immune system 
to react.  
 
There are some differences between the peptide loading of HLA-A, -B and -C. The PLC 
stabilizing the HLA class I molecules include a molecule called tapasin which can trim 
peptides about to bind the HLA class I complexes. This process enhances the variability 
of the peptides yielded by the proteasomes. HLA-A and HLA-C bind the PLC quite 
nicely while HLA-B does not [12]. HLA-B molecules can instead be loaded with 
peptides directly in the lumen of the endoplasmic reticulum, and the HLA peptide 
complex is therefore transported to the surface faster than HLA-A and -C. Most HLA-B 
molecules are loaded with peptides, while only 30-70% of the HLA-A and HLA-C 
molecules are loaded [9].  
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2.1.2 Class II molecules 
The HLA class II molecules consist of two amino acid chains, one α-chain and one β-
chain of equal size. Both chains can be polymorphic but the β-chains are by far the 
most polymorphic and are encoded by any the three classical genes HLA-DRB1, HLA-
DQB1 and HLA-DPB1. The α-chains are encoded by the HLA-DRA, HLA-DQA1 and 
HLA-DPA1 genes respectively. On some haplotypes there are extra HLA-DRB genes 
thought to originate from duplication of the DRB1 gene. These are called DRB3, DRB4 
and DRB5 and are also expressed but at a lower level than DRB1. The chains pair up in 
the endoplasmic reticulum lumen and associate with a peptide binding cleft molecule 
called the invariant chain which prevents binding of self-peptides that are restricted to 
HLA class I molecules. The molecules are then transported to some late endosomal 
compartments, containing peptides derived from the endosomal pathways. The 
invariant chain is degraded and the HLA molecule binds a 14-20 amino acids long 
peptide. The HLA class II molecules have a binding cleft that is open in both ends 
which facilitate binding of longer peptides than HLA class I. The molecules are then 
further transported to the surface for antigen presentation to CD4+ T-cells. The HLA 
class II molecules present mainly peptides derived from the surrounding environment 
of the cell. Extracellular components engulfed by the cell are degraded via endosomes 
and lysosomes. The peptides generated in that process will bind to HLA class II when 
the invariant chain is degraded. HLA class II molecules are normally only expressed on 
antigen presenting cells (APCs) but other cells can induce expression if exposed to 
IFN-γ.  
 
2.1.3 Cross presentation 
The restrictions of peptide binding described above are usually what the bulk HLA 
molecules present. There are pathways that introduce foreign peptides on class I 
molecules and self-peptides on class II molecules. One pathway that has been in focus 
lately in autoimmunity is autophagy, a mechanism for regulation of protein turnover by 
engulfment of cytoplasm. The content of the autophagosome is then degraded via the 
lysosomal pathway resulting in self-peptide presentation on class II molecules [13]. 
Autophagy is heavily studied and considered as a mechanism of principal importance 
in Crohn's disease [14]. 
 
2.2 GENETIC VARIABILITY WITHIN HLA 
There are structural and genetic similarities between the HLA molecules that are 
thought to originate from duplication of genes during evolution. Variability of the HLA 
has helped the human species to survive through times of selective pressure by, for 
example, pathogens. With a wide range of variants in a population, the probability of 
some individuals to survive an infection of a fearsome pathogen increases and thereby 
the species survives at the expense of those carrying variants not so beneficial. For 
every generation, variability changes within a population and to quote something I 
heard in a seminar –“Nature doesn’t care about the individual, it only cares about the 
species” summarizes this quite well. The HLA gene region on a chromosome can be 
seen as a patchwork of different variable regions that are highly polymorphic between 
individuals. However, certain combinations are more often seen than others within a 
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population. One such example is the ancestral B8 haplotype that has been intensely 
studied. It contains HLA-A*01, HLA-B*08 and HLA-DRB1*03 and is the most common 
haplotype in Caucasians. The naming of HLA gene variants is complicated and the 
HLA nomenclature has been revised several times during the years. An example can be 
seen in figure 2. 
 
 
Figure 2. This is an example of the naming of an allele. Picture adapted from 
www.hla.alleles.org. This thesis focuses on the allele groups, black portion. 
 
The patchwork of combinations of these chromosomal regions put together, forming 
the HLA haplotypes we see today, is a result of many generations of recombination, 
selection, duplications and deletions of genes. Some haplotypes are more common than 
others and some are even new. It is a characteristic of the HLA gene region that makes 
it problematic to analyze its effect on disease susceptibility. Grouping the genetic 
material into variants that encode proteins that share physical properties in a similar 
way or a subgroup within those, is a way to reduce heterogeneity between the 
individuals. But in doing so, one usually have a hypothesis of on what level of HLA 
resolution the susceptibility to the disease is present.  
 
There are many alleles in each classical gene and the most diverse of them is HLA-B 
with a remarkable 2,338 alleles registered in the IMGT/HLA database 
(http://hla.alleles.org, accessed 6 April 2012). These alleles encode 1,795 proteins, 
meaning that almost 77% of the genetic variants encode unique proteins (Table 1). 
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Table 1. Number of alleles and protein registered in the IMGT/HLA database at the 
date of access. 
Classical gene  Alleles Proteins 
Ratio 
P/A
HLA‐A  1757 1290  0.73
HLA‐B  2338 1795  0.77
HLA‐C  1304 946  0.73
HLA‐DRA  7 2  0.29
HLA‐DRB1  1166 873  0.75
HLA‐DQA1  47 29  0.62
HLA‐DQB1  162 113  0.70
HLA‐DPA1  33 16  0.48
HLA‐DPB1  152 131  0.86
P/A ratio = number of proteins / number of alleles 
 
All this variation is a source of endless information but makes it hard to determine 
which exact variant an individual have. There are today several methods that can be 
used and in my studies many of them are represented. I have myself used the Olerup kit 
with sequence specific primers (Olerup SSPTM HLA low resolution Kit [15]) that 
detects the serological type, i.e. at the two digit level (Figure 2). This level of HLA 
resolution corresponds to groups of proteins that respond similarly to specific stimuli. 
Genotyping of HLA-B was done by personnel at the department of Clinical 
Immunology and Transfusion Medicine at Karolinska Sjukhuset Huddinge which had a 
long experience of HLA genotyping with a Luminex based reverse PCR sequence 
specific oligonucleotide method (LabType® SSO from One Lambda, Inc., Canoga 
Park, USA). This method detects PCR amplified sequences with beads and returns 
groups of alleles positive for that sequence. I reduced those to two digit level for our 
analysis.  
 
With large genome wide association studies (GWASs), with large amount of SNPs 
genotyped throughout the HLA region it is possible to impute alleles based on LD 
between the SNPs. This method is still under development as more and more 
populations are genotyped and the results so far is that imputation is fairly good, 
excellent for some alleles but not so good for others. This is probably due to that the 
SNP chips used only can design probes for some SNPs and not others and that not so 
common alleles are avoided. 
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3 HLA IN COMPLEX DISEASES 
 
MS is a complex disease, or a multifactorial disease, meaning that it is not caused by 
one single factor but rather a combination of factors. An even more complicating aspect 
is that these factors may not be the same for all patients. It probably depends on 
underlying interactions between factors if disease is developed or not. It is for example 
not enough to smoke to get lung cancer even if it in itself is a strong risk factor. Many 
people smoke their whole life and never develop lung cancer and some people get lung 
cancer even though they have never smoked. The risk factor has reduced penetrance 
meaning that the probability of getting disease if positive for the risk factor is not 
100%. An individual has a genetic make-up that makes it unique. As a result of 
genetics and surrounding factors the individual will take certain steps in life that expose 
the individual for all kinds of different environments that affect susceptibility for life 
time events such as accidents or diseases (both chronic and temporary). Some will 
develop this or that disease during their lifetime, some will not. Those factors that we 
manage to pinpoint as risk factors for disease are not exclusive for the patients; 
otherwise it would be a “monofactorial” disease. These factors are to some extent also 
present in controls and therefore some other, unknown contributing effect induces 
disease in combination with the known risk factor. 
 
3.1 HLA IN AUTOIMMUNE DISEASES  
Several diseases with features common to MS are associated with certain HLA alleles, 
especially autoimmune diseases. The larger genome wide association studies have 
found several genes that seem to be important in many diseases pointing toward key 
factors that could tell us more about different disease pathways. However, most often 
does one allele increase risk of one disease and the other allele increase risk for another 
disease. This scenario fits rather well with the notion that the genetic landscape one 
carries together with the environmental factors increase the risk for some diseases and 
decreases it for others. HLA genes are such genes with different risk for disease 
depending on variant, but what role HLA play in these diseases is not always known. 
 
3.1.1 Type 1 Diabetes 
Type 1 diabetes (T1D) is an autoimmune disease where the insulin producing β cells in 
the pancreas are destroyed in a process that starts already in childhood. HLA class II 
genes account for up to 50% of the genetic risk of T1D, as reviewed in [16]. The class 
II variants responsible for this association are two positively associated haplotypes, one 
being DRB1*03,DQA1*05:01,DQB1*02:01 shortly called DR3 and the other one is 
DRB1*04,DQA1*03:01,DQB1*03:02 shortly called DR4. These are common 
haplotypes in Caucasians, but up to 95% of all T1D cases carry at least one of them. 
There is one negatively associated haplotype, the MS risk haplotype, 
DQA1*01:02,DQB1*06:02 which is dominantly protective in T1D. The rest of the 
haplotypes confer a spectrum of risks varying from protective to mildly increasing the 
risk of T1D.  
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3.1.2 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disease where chronic inflammation of 
smaller joints is the main symptom. About 1% of the world wide adult population is 
affected. The HLA is the most important genetic risk factor in RA and accounts for up 
to 50% of all the genetic risk for RA (reviewed in [17]). There is a “shared epitope” 
hypothesis applied to HLA in the RA field, where a conserved amino acid sequence can 
be found within several allele groups. These shared epitopes can be found in HLA-
DRB1*04 and DRB1*01 and it is only associated with ACPA (anti-citrullinated protein 
antibodies) positive RA, thereby distinguishing a genetic difference between ACPA 
positive and negative RA. There is a hypothesis that the shared epitope HLA molecules 
are involved in shaping the T-cells to become autoreactive. In ACPA positive RA, 
protection is associated with DRB1*13:01. The ACPA negative RA is instead 
associated with DRB1*03 that is not part of the shared epitope allele groups and there 
seem to be no protection from DRB1 alleles for this type of RA. 
 
3.1.3 Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is an autoimmune disease where symptoms can 
vary and diagnosis is made on basis of a set of criteria. The main phenotype is that the 
patient is positive for autoantibodies directed against nuclear antigens. In SLE, the main 
associations to HLA are found with three haplotypes, DRB1*15:01,DQB1*06:02, 
DRB1*08:01,DQB1*04:02 and DRB1*03:01, DQB1*02:01, as reviewed [18]. 
However, there are also genes in the HLA class III region that are important for SLE 
susceptibility. Among those are complement genes involved in innate immunity. 
 
3.1.4 Celiac disease 
Celiac disease is an autoimmune disease that is induced by eating gluten and can 
therefore also be reversed by stopping the intake of this protein. The disease has a 
strong association to HLA-DQA1*05, DQB1*02 and DQA1*03,DQB1*03:02, the same 
as the major risk haplotypes for T1D. These two haplotypes are the main risk variants 
and those that do not carry either of these two, carry haplotypes where DQA1*05 or 
DQB1*02 is present. These HLA allele groups are necessary for developing disease but 
not always sufficient [19]. It is thought that very stable gluten peptide binding to these 
HLA molecules is responsible for the strong activation of the immune system. The 
perfect matching shape of the peptides is enhanced by the activity of transglutaminase 2 
enzyme. 
 
 
3.2 MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disease of 
the central nervous system (CNS) that has a strong inflammatory component. It is 
diagnosed by a wide set of criteria of which some combinations have to be fulfilled. 
The criteria have been revised during the years, such as the Poser or McDonald criteria 
[20, 21]. Hallmark investigational findings carried by many patients are presence of 
IgG antibody production (called oligoclonal bands) in the cerebrospinal fluid (CSF) not 
seen in plasma and inflammatory lesions in the brain detected by magnetic resonance 
imaging (MRI) separated in time and location. Examples of symptoms in MS patients 
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are fatigue, numbness, muscle weakness, pain, cognitive impairment and blurry vision 
[22]. MS is divided into two courses and about 5-10 % of patients follows the primary 
progressive course (PPMS), gradually getting worse but do not really have any bouts of 
symptoms. Relapsing remitting course (RRMS), also called bout onset MS, is the most 
common form and patients get bouts of symptoms but recover back to normal function 
in between. As time goes by the ability to fully recover between the bouts is reduced 
and the patients gradually enter the secondary progressive phase of bout onset MS 
(SPMS). In this phase the patients gradually worsen and the bouts are more or less 
absent as in primary progressive course. Patients with bout onset MS can have very few 
bouts or very many and every number in between, it can vary through the years and the 
length of the relapses differs from patient to patient and from time to time. MS is more 
common in women than in men while men more often develop the PPMS subtype. A 
geographical gradient describes a higher frequency of MS in areas closer to the poles 
than to the equator, a finding that has stimulated hypotheses on the effects of sunlight, 
vitamin D and ancestral genetic heritage from the Vikings. 
 
In monozygotic twin pairs where one individual is affected with MS, only 1/5 of the co-
twins are also affected. This is usually a way to describe that not only genetics is part of 
disease susceptibility since monozygotic twins are considered genetically identical. On 
the other hand, the risk for the healthy twin to develop disease is much greater than for 
an individual in the general population with no relatives diagnosed with MS (lifetime 
risk 1/500), thereby indicating that genetic predisposition also is important.  
 
Recombinant interferon beta (IFNβ) is a first-line therapy for RRMS. The therapeutic 
effect of IFNβ in MS has been investigated in a number of trials, which have shown 
that IFNβ reduces the number of clinical relapses and new lesions, as well as the 
accumulation of disability over time [23-25]. The understanding of the mechanisms 
behind the disease-modifying effect of IFNβ in MS is still incomplete. 
 
3.2.1 HLA in multiple sclerosis 
The strongest genetic risk factor for MS found so far is the HLA class II haplotype 
DRB1*15:01,DRB5*01:01,DQA1*01:02,DQB1*06:02 [26] efficiently tagged already 
in the 1970-ties by association to class I alleles [27, 28]. This haplotype is present in 
about 60% of the patients and 30% of the controls in our cohort [29] and association to 
increased risk of MS is found in most populations worldwide. Today the negative 
association to MS of HLA-A*02 is also established [29-32]. The function of HLA in 
MS susceptibility is not clear as it is also debated if the inflammation of the brain 
precedes demyelination thereby driving disease, or if it is a result primarily from 
demyelination and that the immune components are trying to clean up the tissue 
damage. Lately, in part due to all the GWAS results indicating roles of immune genes, 
increased evidence point in favor of the former hypothesis [33]. At the same time, new 
studies of neurodegeneration in the brain increase the evidence for the later hypothesis, 
as reviewed in [34, 35]. Thereby both hypotheses gain more evidence and research 
around the early diagnosed MS cases might help to resolve this question. 
 
What has been observed is that CD4+ and CD8+ T-cells seem to have a central role in 
pathogenesis. It is thought that a lesion forms when, for some unknown reason, T-cells 
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start attacking the myelin producing oligodendrocytes in the brain. Myelin basic protein 
(MBP) and myelin oligodendrocyte protein (MOG) are two components of the myelin-
derived isolating sheaths around the axons in the CNS, and the proteins are released 
when the myelin sheath is disrupted. Without the myelin sheath, the axons are no 
longer protected from surrounding influx of ions and the conduction of neuronal 
impulses is heavily reduced or even eliminated. The blood brain barrier close to these 
lesions is often disrupted making it easier for immune cells to enter that normally 
would not access the CSN. The destruction of myelin sheaths, axons and also nerve 
cells results in the loading of HLA molecules on surrounding APCs with a smorgasbord 
of self-peptides presented on both class I and class II. All the cytokines and other 
released stimulatory molecules activate upregulation of co-stimulatory molecules on 
the APC surface and this is where the hypothesis of epitope sharing comes in. Some T-
cells recognize peptides that closely resemble for example myelin peptides. One such 
T-cell has previously been activated by some infection, recognizing the peptide as a 
“threat” because the APC also display the co-stimulatory molecules that trigger an 
“alarm”-signal in the T-cell. When this cell then finds an almost identical peptide 
generated by degradation of myelin, the recognition and the inflammatory milieu in the 
lesion activates the T-cell again and it starts to proliferate and generate many more cells 
of the same kind and autoimmunity against the myelin derived peptide is born. This 
“epitope spreading” is a part of a larger concept of molecular mimicry which is an 
example of how lesions can arise and prevail [36], but there are some evidence that 
support it. Many viruses have been investigated in MS but few reports have been 
confirmed. There is increasing evidence for a role of previous exposure to Epstein-Barr 
virus (EBV) preceding the MS diagnosis and a potential link to HLA [37, 38]. EBV 
derived peptides could be the first step in the epitope spreading hypothesis. MOG 
specific T-cells have been isolated in MS patients and are more frequent in patients 
compared to healthy controls [39]. MOG peptides can potentially activate these T-cells.  
 
Studies in animal models have frequently been reporting evidence of how MHC might 
be involved in regulation of experimental autoimmune encephalomyelitis (EAE, the 
MS rodent model). EAE can be induced in susceptible strains by injection of MOG, 
MBP or proteolipid protein (PLP) and the symptoms are similar to RRMS with relapses 
and remissions. Transgenic mice with human class II alleles and no mouse MHC have 
been used to investigate the role HLA have in MS immunopathogenesis. It seems like 
DR molecules are required for EAE susceptibility while DQ molecules act as risk 
modifiers in mouse models, reviewed in [40]. This hypothesis goes hand in hand with 
reports of a Canadian family material where MS family trios have been studied for 
modifying effects of DRB1*15 [41]. It was however not possible to detect such effects 
due to strong LD in the large GWAS done on 9,772 MS cases and 17,376 controls [32].  
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4 MY STUDIES 
 
4.1 PAPER I AND II 
The idea to the first paper in this thesis was already in discussion within the group 
when I started my PhD in Huddinge. This was my first project and I engaged in 
genotyping HLA-C in a cohort where genotypes were already known for HLA-DRB1 
and HLA-A, as part of a project that my supervisor Boel Brynedal published around the 
same time I started in the group [29]. The research group had a good relationship with 
Hanne Harbo´s MS genetics group in Norway and it was decided to make a joint 
project in order to increase power. The aim was to investigate if further signals in HLA 
class I was present in MS and/or if the HLA-A*02 signal presented by Boel was a proxy 
for some other signal that could be picked up by an allele group in HLA-C which is 
located in between HLA-DRB1 and HLA-A on chromosome 6 (Figure 1). At that time 
there were doubts against signals in HLA class I in MS genetics and especially if 
presented with “complex” statistical tests like logistic regression which was met with 
hesitancy by several reviewers. Originally, I didn’t understand anything Boel explained 
regarding her analysis and after showing me repeatedly, she must have been frustrated.  
 
4.1.1 The concept of LD within my data 
When typing DNA all days long, running electrophoresis gels and taking pictures at the 
UV-table, I started to get a grip of the complexity of the HLA, both by reading papers 
that were published, the genotyping data I produced and by all the discussions we had 
within the group. The concept of LD started to sink in when I saw that it was very 
common in my dataset to be DRB1*15 positive and C*07 positive but I could not see 
that clear relationship when looking at HLA-A. I started to form my picture of HLA, 
diplotypes, extended haplotypes and evolutionary conserved haplotypes and realized 
how much more complex it actually was. Was there anything that was not dependent 
on anything else? 
 
4.1.2 Scooped? 
While I was genotyping, several papers, reported class I associations to MS. One of the 
first ones was done by the International multiple sclerosis genetics consortium 
(IMSGC) and the authors reported an association to HLA-C*05 [42]. Their study had 
the same aim as mine but used a mixture of SNP data, microsatellite data and low 
resolution genotyping data in a cohort of British family trios and sporadic cases as well 
as US family trios. The primary feeling was “scooped” but after some discussions we 
realized that there were some important differences between the studies. They had to 
infer their allele groups from different types of data such as micro satellites, SNPs and 
normal HLA genotyping; we had HLA low resolution genotyping from only one source 
in our cohort, giving our study an advantage. Our cohort was almost as large as theirs; 
we thought that if we would see the same results, our paper would be a nice replication. 
We also wanted to study our cohort with another method than what would be used in a 
replication analysis. Those authors practically gave me the instructions in how to 
perform a statistical analysis of HLA association in that paper. Also, we knew already 
at this stage that we wanted to genotype HLA-B due to recent reports of negative 
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associations to B*44, so this would be a perfect practice for me. It was therefore 
decided to continue the study. 
 
4.1.3 Several reports but only one main point 
While I was analyzing the data and writing the paper several other reports of secondary 
signals within the class I region was published. One of those suggested an association 
in the MOG gene located telomeric of HLA-A [43]. In that study, no information on 
classical HLA class I genes was available and a connection to A*02 or C*05 could not 
be studied. Another study used SNP mapping and candidate gene mapping in analyzing 
the connection between MOG and HLA-A in Tasmanians [44]. This study did not have 
HLA-C data and a possible effect of C*05 could not be studied. In addition to these 
other reports an article published by the IMAGEN group was in press before our paper 
was accepted [45] showing a more complex analysis based on SNP data. The authors 
discussed a secondary signal best explained by B*44:02 that emerged when 
conditioning on a SNP in LD with DRB1*15. Cree and colleagues could not rule out 
HLA-A since there were secondary signals also around that locus although not as strong 
as in the HLA-B/-C locus. Also, a report of association to HLA-B*44 was found in a 
meta-analysis of several GWAS scans and the signal was independent of DRB1*15 
[46]. 
 
These papers pointed in different directions but they all said one thing: There is 
something hiding in the class I region and it might be independent of A*02 or even an 
association superior of A*02. The most fundamental problem, apart from the lack of 
HLA-B data, was the statistical approach. How does one take into account the extensive 
LD but still highly polymorphic genes without losing power and using overly 
complicated models? A typical way of analyzing HLA was to stratify the cohort on the 
most associated marker and exclude those individuals from further analysis [47].This 
approach did not seem right, although I couldn’t put my finger on why. It didn’t make 
sense to ignore the other chromosome in those individuals that carried the most 
associated allele group (in our case DRB1*15). What if the carriage of some other allele 
did affect the risk of DRB1*15? There were studies that indicated that that might be the 
case [48, 49]. Even though our cohort was not powerful enough to investigate that type 
of effect modifications did not mean that I could ignore it. Actually it could even mean 
that I possibly would draw the wrong conclusions from the results. Additionally, a 
stratification approach always reduces sample size, which decreases your power. 
 
4.1.4 Recursive partitioning didn’t work 
In an article from the Type 1 Diabetes Genetics Consortium (T1DGC) the authors used 
recursive partitioning to establish risk haplotypes between DRB1 and DQB1 [50], and 
the authors later corrected for a haplotype in regression analysis when searching for 
class I signals independent from class II in T1D. This was a way of reducing the 
influence of HLA class II heterogeneity when searching for independent signals in 
HLA class I. I thought that maybe this could be used within HLA class I to distinguish 
which allele groups had an independent effect of A*02 and DRB1*15. The method 
splits the material on the variable that best separates cases from controls. It continues to 
split the cohort in a tree like fashion until the defined maximum number of nodes is 
reached or the purity of the nodes is no longer significantly better. The first split 
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separated the cohort into one node with DRB1*15 positive and one with DRB1*15 
negative individuals. The purity, i.e. separation of cases from controls, of the nodes was 
significantly better than in the starting material. The second split divided both nodes on 
A*02 carriage, indicating that the effect of A*02 was independent of DRB1*15. The 
purity of the groups was better, but the improvement was not on the same scale as the 
split on DRB1*15. An analysis of purity and complexity of the trees indicated that we 
did not have enough power to study more splits than the first two, the gain of purity did 
not compensate for the increasing complexity of the tree. We could not use this method 
to study effects other than DRB1*15 and A*02 that we already knew of.  
 
4.1.5 Mimicking the IMSGC paper 
To be able to compare the results to the already published paper from IMSGC we had 
to analyze our data in the same manner. The method removed the largest risk allele 
group and thereafter the largest risk allele group in the remaining dataset. First the 
IMSGC authors excluded DRB1*15, then DRB1*03 and after that DRB1*01:03 and 
within the individuals negative for all three alleles, only HLA-C was globally 
significant and within that gene the strongest signal was HLA-C*05 which was 
negatively associated to MS. Either we could do our analysis exactly the same way, 
excluding the exact same alleles or we could use the same method but apply it to our 
data and exclude the alleles that had further signals in our cohort, regardless of if it was 
a different allele group than in the IMSGC study. When excluding the exact allele 
groups (first DRB1*15, then DRB1*03 and DRB1*01:03) as the IMSGC did in their 
study, both HLA-DRB1, HLA-A and HLA-C were globally significant and within each 
of them I had several signals from several allele groups. We decided to instead use the 
same method and apply it to our data. After exclusion of DRB1*15, the most significant 
gene was HLA-C and within that gene the C*08 allele group was the most associated. 
After removal of the C*08 positive individuals, weak signals could be found in HLA-A 
and this result was reported in our paper. 
 
4.1.6 My way of thinking about logistic regression in paper I and II 
In the paper that Boel published, about the same time I started in the group, a nested 
logistic regression was used to study the effects of HLA-A allele groups while having 
DRB1 allele groups as covariates [29]. We decided to use this approach in paper I since 
the method provided a way to correct for already known risk alleles while still retaining 
information on the other chromosomes that would be excluded by a stratification 
approach. Since HLA-C is located in between HLA-A and HLA-DRB1 we had the 
following main objectives: First, to try and map the effect of A*02 and investigate how 
far the signal extend from HLA-A, and whether it was also in LD with something in 
HLA-C. The second objective was to investigate whether there were allele groups of 
HLA-C that were associated with MS independently of A*02 and DRB1*15. For both 
these objectives we turned to logistic regression. The problem was, though, how to 
model the data to be able to draw conclusions in an effective way. First we wanted to 
see if the information on each gene could explain the outcome. When adding HLA 
genes to the regression model, the number of variables increases dramatically due to the 
highly polymorphic state of the genes and this decreases power. Even though this was a 
problem, we could see that all three genes added information that better explained the 
outcome. The fit was best for the DRB1 gene and the next step was to correct for the 
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DRB1 gene and analyze if addition of any of the class I genes increased the fit of the 
model. This was true for both HLA-A and HLA-C but the overall fit of the DRB1 + A 
model was better than DRB1 + C. So the last model was to investigate if the data on 
HLA-C could increase the fit significantly over DRB1 + A, and this was indeed the case.  
 
We could also see that individual allele groups from each gene were associated to MS 
in the final model. The alleles that were associated with MS were mostly DRB1 alleles 
but both A*02 and C*08 was associated even after false discovery rate (FDR) 
adjustment. These were the same alleles that were found in the stratification analysis 
but we could not see the other DRB1 allele group associations in that analysis. Hence, 
the conclusion might be that stratification is not the perfect way to study signals within 
the same locus but more powerful to detect a signal from a second locus.  
 
4.1.6.1 New insights in paper II 
When I got the HLA-B data and the first paper was submitted and more or less done I 
had learned a bit more about logistic regression and realized that the way we did it in 
the first paper was not optimal for the second paper. We compared the genes to each 
other with all allele groups added and in the final model there were almost 30 variables 
included. This is not at all optimal and probably not even possible to draw any 
conclusions from when I now had four genes to study. However, the number of 
variables in my study was a bit deceiving, actually none of them were independent 
from all others and how many variables were then acceptable? In the beginning of the 
analysis I used nested logistic regression as in the first paper but I had problems with 
interpretation of the results and what those actually meant. Was a larger model better 
just because it was more complex? Was it possible to exclude those alleles that were 
not significantly associated? How should we code the allele groups, was dosage more 
informative than carriage or did we assume too much with that model? The discussions 
within the group how to solve this went on every week on the Monday meetings, but I 
am not sure how far we came each week. One of the break points came one day from 
an unexpected source. A colleague was in Stockholm visiting our laboratory and as a 
statistician, immediately pointed out the obvious problem that the final model had too 
many variables. We had to reduce it somehow; there was no other choice in this case. 
That was all it took for turning the project around, we finally got some straight forward 
directions on how to pursue this project. I am very grateful for that input, and the funny 
thing was that we had discussed it but none of us actually knew what “too many 
variables” meant, where do you draw the line? It most certainly depends on the 
hypothesis and that’s when my brain started questioning that concept. What was our 
hypothesis exactly? Under which circumstances did this apply, and under what model? 
What was previously known that was relevant to use, what questions can logistic 
regression answer, what level of association is meaningful and in what setting should 
the questions be asked? The questions went on until a clearer picture of how I wanted 
to analyze the project emerged. A change in tactics was needed. 
 
4.1.6.2 Logistic regression reloaded 
While the genotyping of HLA-B was outsourced to save DNA and reduce my hours in 
the lab, new papers had come out that studied the signals in class I. Most of the papers 
reported independent effects of HLA class I allele groups on top of DRB1*15 but no 
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overall conclusion was made. There were reports that the protective effect of A*02 was 
enhanced by carriage of C*05 and that C*05 could be a risk factor if carried together 
with DRB1*03 [51]. The authors only genotyped for the specific allele groups of A*02 
and C*05 and could therefore not take any other allele group into consideration. A year 
later a follow up study was published where they had added data for presence or 
absence of B*44 and B*18 [52]. The main finding from this paper was again that C*05 
enhanced the protection of A*02 and that the haplotype maintained the protection when 
correcting for B*44 but the authors ignored the fact that C*05 did not have any effect at 
all when correcting for A*02 and B*44. C*05 was not associated to MS when 
correcting for only B*44, and showed independent negative association when 
correcting for A*02 in the family material they analyzed but not in their case control 
cohort. The allele groups seemed to be connected to MS susceptibility in some way that 
was not so easy to study. The protective association also seemed to be a bit different in 
different populations, in some the main effect came from B*44, in some from A*02 and 
in some C*05 modulated the protective effect. All this information taken together made 
me curious if they actually were one and the same signal but that it was masked 
between populations by allele group haplotype frequencies. This would also explain 
why the big IMSGC GWAS did not find any more signals in class I when correcting 
for DRB1*15 and A*02 [32]. Only DRB1 alleles were reported to have residual effects 
in that study. That was how my hypothesis about a protective class I haplotype was 
born. 
 
Going back to the scientific question, I didn’t just want to study the previously reported 
associations of A*02, C*05 and B*44. I had complete allele group information on all 
four genes in 1,784 patients and 1,660 healthy controls, genotyped specifically for the 
HLA genes and not inferred from SNP data, which was something no other group had. 
We felt obliged to investigate MS susceptibility in a more hypothesis free approach, at 
least to start with. So, what could I really use logistic regression for and should I 
exchange it for something else? I realized, when looking deeper into the concept of 
logistic regression, that it is mainly a way to study a factor when you want to adjust for 
some kind of relationship to another factor. One conclusion from a logistic regression 
analysis is what effect the variable of interest has on the outcome in the population 
when all other variables included are held fixed. That meant that I could use the logistic 
regression in a different way than I initially thought. Instead of adding one gene to the 
other in a nested way, I studied one gene at a time at first. What we tried to use the 
nested logistic regression for in the first paper was to adjust for the long range LD that 
is present in HLA. However, I turned it around a bit and thought that actually if there 
was long range LD between the genes that were of possible importance I should be able 
to pick those signals up within each one of the genes. After reducing the complexity 
within each gene, I could adjust for the other genes to remove hits that were due to LD 
with other more strongly associated alleles. The long range LD hits would then be 
redundant and the best signal should be kept by the model and those associated allele 
groups that were not part of long range LD would be adjusted for all other effects 
within our material and either hold for the adjustment or be excluded. In this way I 
reduced the number of variables in the final model, corrected for long range LD and at 
the same time the analysis was as unbiased as I could manage. However, the effects of 
DRB1*15 and A*02 were at this time more or less established and this complicated the 
concept a bit. 
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Another problem was under which model the allele groups should be coded in the 
analysis described above. We could no longer ignore the prior knowledge about 
DRB1*15 and A*02. In our cohort, the OR for MS for those carrying one copy of 
DRB1*15 is around 3, for the homozygotes the OR is much higher, around 11 in our 
cohort. This huge effect could not be found for A*02, which seemed to act in a more 
dominant fashion; the presence of any A*02 allele reduced the risk of MS similarly as 
the presence of two A*02 alleles. How all the other alleles should be coded was more or 
less impossible to predict. Therefore, I decided two things. First, I wanted a baseline 
model where I had the two already established risk factors for MS coded as correctly as 
possible given the previous results. Second, I wanted to study what the difference was 
between coding the rest of the alleles for carriage or dosage. Did it actually matter in 
my analysis? If there was no difference the model with fewer categories would be 
preferable due to reduced complexity.  
 
I performed the analysis first with all allele groups coded as the number of alleles from 
a particular allele group (0, 1 or 2) and second with all allele groups coded as presence 
of any allele from the allele group (0 or 1). They were both compared with the same 
baseline and that baseline contained gender, country of origin, DRB1*15 coded as 
number of DRB1*15 alleles and A*02 coded as presence or absence of A*02 alleles. 
Both underlying hypotheses (carriage or dosage effect) included four sub analyses and 
one last final model. The first four tests were performed within each gene, i.e. one per 
gene. All allele groups within DRB1 with a certain frequency was added to the baseline 
variables and those not significantly associated to MS was removed until only 
associated allele groups were left. When this was done for all four genes, all the alleles 
associated to MS were added into the final model to remove possible LD effects or at 
least adjust for it. Also here the non-significant allele groups were removed. I should 
perhaps mention that a sacrifice was made within each gene. I had to exclude one allele 
in each locus from the analysis, otherwise the first entered allele group within each 
gene was used as intercept whether I wanted it or not. My dataset did not contain any 
individuals that were “zeros”, i.e. didn’t have any allele group. Therefore I had to 
decide which allele group I wanted as intercept within each gene. After careful 
consideration I chose the allele group that was most equally distributed between cases 
and controls and had an allele frequency over some threshold that was fairly common 
in the cohort. This is something that can be debated, especially within DRB1 since 
almost every major allele group at that gene has been reported to affect MS 
susceptibility in some way, as reviewed in [53].  
 
4.1.6.3 Logistic regression revolution 
When I had my two final models built on different underlying assumptions, the allele 
groups either acted dominantly or in a dosage fashion, I compared them to each other 
and discovered that both models contained the exact same allele groups. The estimates 
and the confidence intervals only had small differences and the overall fit of the model 
was a bit better with the carrier coded model. So the final result was the same and it 
didn’t seem to matter whether I coded alleles as carriage or dose. The main difference 
between the two assumptions was that dosage was a bit stricter in defining associated 
alleles within each gene while the carrier model allowed for more allele groups to be 
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associated with MS but these were later pruned from the final model due to LD with 
effects from other allele groups (Table 2).  
 
Table 2. Comparison between the two different ways of coding the allele groups in the 
logistic regression. 
Dosage 
Model   Model terms,  significant alleles 
Model 
comparison  ΔDeviance  ΔDf 
    p‐
value  
1  Baseline              
2  BL + B alleles (B*12, 14)   Model 2 vs.1  39.1  11  5.14x10‐05
3  BL + DRB1 alleles (DRB1*01, 07)   Model 3 vs.1  16  7  0.025
4  BL + A alleles (nas)  Model 4 vs. 1  5.4  6  0.5
5  BL + C alleles (nas)  Model 5 vs. 1  18.3  10  0.049
6 
BL + B*12, B*14, DRB1*01, 
DRB1*07  Model 6 vs. 1  37.6  4  1.39x10‐07
Carriage 
Model   Model terms , significant alleles 
Model 
comparison  ΔDeviance  ΔDf 
    p‐
value  
1  Baseline             
2  BL + B alleles (B*07, 08, 12, 14, 17, 40)   Model 2 vs.1  44.9  11  5.07x10‐06
3  BL + DRB1 alleles (DRB1*01, 03, 05, 06, 07)  Model 3 vs.1  24.8  7  0.00083
4  BL + A alleles (nas)  Model 4 vs. 1  6.8  6  0.3
5  BL + C alleles (C*05)  Model 5 vs. 1  22.8  10  0.011
6 
BL + B*12, B*14, DRB1*01, 
DRB1*07  Model 6 vs. 1  41.4  4  2.22x10‐08
ΔDf = delta degrees of freedom, indicates how many variables (allele groups) that differ between the two 
models compared. BL = baseline, nas = no allele group significantly associated to MS 
 
I chose to use the data from the carriage model as primary results in paper II. In that 
final model we found association to MS of DRB1*01 and DRB1*07 within DRB1 and 
B*12 and B*14 on top of our baseline containing A*02 and DRB1*15. B*12 contains 
the subtypes B*44 and B*45. B*14 is in tight LD with C*08 which I found associated 
to MS in the first paper. B*14/C*08 is a quite rare allele group and I am not confident 
in the ability for others to replicate that finding. This association may very well be 
sample specific. The cohort in paper II is not suitable for replication of the findings in 
paper I since many individuals were included in both studies even though new subjects 
were added in the second paper. It is possible to confirm that A*02 is still associated 
with MS even after adjusting for HLA-B allele groups in this cohort. 
 
Even though logistic regression adjust for DRB1*15 in this setting I wanted to see if 
any allele group had an independent effect within the DRB1*15 positive or negative 
groups. Therefor I stratified the cohort into two groups according to DRB1*15 status 
and performed a logistic regression within each group when the effect of carrying 
DRB1*15 was completely removed. In the DRB1*15 positive group DRB1*15 was still 
associated since several of the subjects were homozygous and as we already knew, this 
increases the risk of MS. That was not surprising, and the association to A*02 in each 
of the DRB1*15 strata was not surprising either but rather a nice confirmation of the 
independency of A*02 from DRB1*15. What was surprising however, was that the rest 
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of the allele groups that was found associated in the total cohort showed association to 
MS in one of the strata, never both (Figure 3).  
 
 
Figure 3. Comparison of how the allele groups associated to MS in the full cohort were 
associated within the DRB1*15 positive and negative strata. The right side squares 
also display which allele groups that reached significant association to MS in this 
setting but was not found in the full cohort. Figure based on Table 1 and Table 2 in 
paper II where details of odds ratios, p-values and frequencies can be found. 
 
This result prompted us to investigate possible interactions with DRB1*15. DRB1*01 
was seen to decrease the risk of DRB1*15 more than was expected from the overall 
effect of DRB1*01. The same trend was seen for C*12 and somewhat also for A*02. It 
is hard to say exactly what this type of interaction means. Obviously the carriage of, for 
example, both DRB1*01 and DRB1*15 does not resemble the expected risk 
modification within this cohort but if this result is due to an actual physical interaction 
resulting in attenuation of risk to MS would be nothing but speculation. The interaction 
only tells me that these two factors do not follow the expected rules I set up in the 
model. Subjects might have more use of this combination of class II allele groups when 
fighting some pathogen or complement each other with other factors also present on 
these haplotypes. It doesn’t have to be DRB1*01 at all, but rather something in LD with 
it. DRB1*01 is perhaps more expressed or even lowers the expression of DRB1*15 
thereby reducing its influence in MS susceptibility.  
 
When repeating the analysis found in the Italian paper, adjusting for allele groups and 
studying one variable at the time [52], I could not replicate the finding where C*05 
enhanced the protection of A*02. The overall result from that analysis in this cohort 
was in fact that C*05 seemed to have no effect what so ever when adjusting for B*12 or 
A*02 or both.  
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4.1.7 Haplotypes of allele groups 
When trying to estimate the haplotypes in the HLA region I encountered annoying 
problems. At first the program UNPHASED 3.1.4 had the maximum limit of only 16 
alleles. Normally, this is no problem, but for me it was crucial to use all the information 
I had on each individual. That meant that I did not group the less frequent allele groups 
in each gene into one “X”-group, and when that was entered in UNPHASED 3.1.4 it 
refused my kind commands. I had to use an earlier version and the most recent one that 
accepted a higher number of alleles was UNPHASED 3.0.13. Then the next problem 
appeared, my computer was not equipped to handle the amount of RAM the process 
consumed. A colleague of mine had a computer more suitable for the analysis but still 
the software complained, the data was too complex for the standard settings which had 
to be adjusted; the software then did the calculations in approximately a week.  
 
The reliability of each estimated haplotype is given by the estimation procedure and I 
only used those individuals whose probability were greater than 80%. The results were 
nonetheless almost the same when including all haplotypes or only those with high 
probability. Individuals that were excluded mostly had unusual haplotypes of which I 
wouldn’t be able to draw any conclusions anyway. In my first analysis I wanted to see 
if any of the 20 most common haplotypes in the cohort affected MS susceptibility. 
Logistic regression was used to adjust for carriage of more than one of the most 
common haplotypes. Indeed most of the associated haplotypes contained one or more 
of the alleles that were seen associated on their own. What could easily be seen in 
Table 3, was that the haplotypes carrying DRB1*15 was more common in patients than 
in controls and most exhibit significant association to MS. Also A*02 showed a pattern, 
being mostly protective, but only as long as the haplotype did not carry DRB1*15. 
Somehow A*02 do not decrease the effect of DRB1*15 on its own but in concert with 
C*05 and B*44 which is a neutral haplotype in our cohort. The question was if these 
three allele groups were adding protection by simply being present in one individual, if 
it was the haplotype in itself or if they tagged something else that was important in MS 
susceptibility. 
 
Table 3. (Adapted from Paper II:Table 4). The table shows the most common 
haplotypes in the cohort, all entered into a logistic regression to account for an 
individual carrying two of them. Neutral DRB1*15 haplotype is underlined. 
 
 26 
FDR = false discovery rate, correction of the p-value to account for the probability of false positive 
findings CI = confidence interval, an estimation of in which range the populations´ OR would be found. 
 
I tried to answer these questions by first studying the independence of the haplotype to 
DRB1*15 and found that it was independent. I investigated the importance of the class I 
allele groups presence on protective ability of the haplotypes. A*02 together with B*44 
was enough to reach the same level of protection as the full haplotype although the OR 
was a bit lower when also C*05 was present on the chromosome. Finally, the change in 
OR between carrying only the haplotype, DBR1*15 and both was studied. DRB1*15 
carrying haplotypes had an increased risk of disease, haplotypes carrying A*02, B*44 
and C*05 had a decreased risk of disease and haplotypes positive for both DRB1*15, 
A*02, B*44 and C*05 did not differ in risk of disease from those not carrying 
DRB1*15 or the full protective haplotype. 
 
The conclusion, that the haplotype of A*02, C*05 and B*44 is protective in MS, needs 
to be verified in some other cohort. To my knowledge, this approach has only been 
performed once before in a case control material in MS, and that was in Sardinia in 
2001 [54]. That population is genetically more isolated and the association pattern of 
HLA to MS is different than in northern Europe and my study cannot really be used as 
a replication cohort in that sense. It would be nice to investigate this haplotype in some 
cohort more similar in genetic etiology. 
 
 
Haplotype 
No. H
LA
-A
 
H
LA
-C
 
H
LA
-B
 
D
R
B1
 
Frequency 
Cases (%) 
Frequency 
Controls 
(%) 
FDR 
corrected 
p-value 
Odds Ratio 
(95% CI) 
1. 1 7 8 3 7.0 8.6 0.033 0.78 (0.63-0.96) 
2. 3 7 7 15 7.6 4.2 2.28x10-06 1.90 (1.49-2.44) 
3. 2 7 7 15 6.0 2.1 2.72x10-11 3.14 (2.31-4.34) 
4. 2 3 15 4 1.8 3.1 0.015 0.60 (0.42-0.87) 
5. 3 4 35 1 1.4 2.6 0.0087 0.54 (0.36-0.81) 
6. 2 5 12 4 0.8 2.9 1.60x10-06 0.28 (0.17-0.45) 
7. 9 7 7 15 2.6 0.8 8.33x10-06 3.30 (2.06-5.47) 
8. 2 3 40 6 1.3 2.0 0.097 0.67 (0.43-1.03) 
9. 10 12 18 15 1.5 0.8 0.021 2.00 (1.19-3.48) 
10. 3 3 15 4 1.1 0.5 0.016 2.35 (1.27-4.52) 
11. 1 6 37 15 1.2 0.4 0.00095 3.87 (1.97-8.35) 
12. 2 5 12 15 0.8 0.8 0.82 0.92 (0.51-1.69) 
13. 1 7 7 15 1.0 0.5 0.032 2.15 (1.15-4.19) 
14. 11 4 35 1 0.7 0.8 0.68 1.19 (0.63-2.23) 
15. 19 16 12 7 0.7 0.8 0.82 0.93 (0.49-1.74) 
16. 19 3 40 4 0.4 1.1 0.015 0.38 (0.18-0.74) 
17. 2 7 8 3 0.5 0.9 0.10 0.56 (0.29-1.05) 
18. 2 3 40 4 0.6 0.9 0.26 0.65 (0.34-1.25) 
19. 2 3 15 6 0.5 0.9 0.28 0.67 (0.34-1.27) 
20. 3 7 7 4 0.5 0.6 0.72 0.85 (0.42-1.71) 
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4.1.8 Perspectives from papers I and II 
I have already in the text above discussed some issues that had to be dealt with when 
doing these two studies, especially regarding the most appropriate way to analyze the 
association to HLA in a complex disease. Given the result from my two studies and the 
information others have published I would say that two things are more important than 
others when going further with these studies. First, my associations are based on allele 
groups. Within a group of haplotypes, the protection might be located only within a 
subgroup of these alleles. When I create haplotypes with allele groups on other genes, I 
study a subgroup within the allele group meaning that it might be a sub allele group 
within either A*02 or B*44 that harbor the protection to MS that just happens to be 
refined when adding info on HLA-C for example. Therefore the analysis of alleles 
within this cohort is warranted. However, my second thought is that it could also be 
possible that the protection to MS is not located within the classical HLA class I genes 
at all but something else on the chromosomes positive for A*02 and B*44. This would 
explain why the LD to different allele groups in other populations is following similar 
but still show a bit different patterns, in Italy more linked to A*02 and the  A*02-C*05 
haplotype and in Britain more linked to B*44 and/or C*05. In Canadian family studies 
no signals was seen in class I at all after correcting for DRB1 allele groups [55]. 
However there is a debate within the field that the role of class I and class II may differ 
between populations due to different LD structures and this was highlighted in the 
commentary that followed the Healy paper where B*44 was found to be protective in 
certain MRI outcomes and MS susceptibility [56]. 
 
I am not convinced that I succeeded in finding the answer to if there are one or two 
protective effects in class I. I would like to rule out the role of C*05 as being protective 
in itself but the role of refining a protective haplotype within the allele groups A*02 and 
B*12 is still possible. My results can however not distinguish if A*02 and B*12 are 
totally independent protective signals or if they are part of the same signal, it seems to 
be a combination of both which is a bit confusing and frustrating for me. When 
correcting for DRB1*15 and A*02, B*12 is still significantly associated to MS, hence 
an independent signal. C*05 is not associated to MS at all when correcting for either 
A*02 or B*12, hence not independent. When studying haplotypes with both A*02 and 
B*12 the odds ratio is not that different from that of the A*02- C*05 - B*12 haplotype. 
But the haplotypes carrying only A*02 or B*12 both have significantly higher risk than 
the protective haplotype; hence the effect of having them on the same haplotype is 
more beneficial for MS risk. 
 
4.2 PAPER III 
In February 2009, a study from Ebers´s group about a vitamin D response element in 
the promoter region of the DRB1*15:01 allele was published and this was the basis to 
the collaboration and publication of paper three in this thesis [57]. The background to 
this story was that a month of birth effect had been seen in MS that suggested that 
individuals born in the spring had a higher risk of  MS later in life and those born in late 
fall had an decreased risk of MS, this has later been observed in both hemispheres [58-
61]. As the interest for the vitamin D hypothesis in MS literally exploded within our 
field, the paper from Ebers group received much attention. It was the perfect 
explanation for everything! The geographical gradient in MS risk, here explained by 
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degree on sunlight, interacting with the largest genetic risk factor (DRB1*15) was 
something that would put some pieces together in the MS puzzle. It was in this light we 
did this study. Looking back, reading all the criticism around the publication that was 
part of the basis for this study, I realize that paper III might have been based on 
something neither true nor replicable [32, 62, 63]. Today, I would hesitate to draw the 
same conclusions as then and I would have analyzed it in a different way.  
 
The basic assumptions for this study were that DRB1*15 bearing haplotypes harbor a 
vitamin D response element that regulates expression of the gene. The hypothesis was 
that vitamin D deficiency during pregnancy or early childhood could affect the risk of 
MS later in life. In the paper we saw an increase of April births among the DRB1*15 
positive patients compared to the DRB1*15 negative patients. We also saw a decrease 
in births in November for DRB1*15 positive patients. These effects could not be seen 
within the controls.  
 
If repeating the study, I would look for MS risk within DRB1*15 positive and MS risk 
within DRB1*15 negative for each month, not the other way around as we did in the 
paper. In this way we also would correct for a possible effect of DRB1*15 on month of 
birth in general, which might be a confounder. Today, my first analysis would be to 
check if there is a month of birth effect at all in this cohort. Second, I would assess the 
power of the study to detect a difference similar to the ones in the larger studies such as 
the one from Willer et al [61]. If we have sufficient power, an analysis of a possible 
DRB1*15 effect could be warranted. If we don’t have power even when not splitting 
the material up, I would suggest a careful interpretation of the results and correction of 
p-values. This was not done in the published paper. 
 
After this paper was published, there have been several studies about vitamin D and 
factors surrounding that pathway in MS. The hypothesis that vitamin D levels influence 
expression of DRB1*15 and thereby the risk of MS have shifted towards the idea that 
lower levels of sunlight can increase risk of MS independent of HLA alleles, as was 
outlined in an Australian meta-analysis [64]. Also, a month of birth effect was not 
found in a large GWAS [32] and a month of birth effect was not connected to 
DRB1*15 in Finland [62]. The degree of reduced sunlight exposure further away from 
the equator coincide with an increased population frequency of the DRB1*15 allele and 
MS prevalence, thereby making it hard to distinguish which is the primary factor 
responsible for this effect. An investigation of the relationship between vitamin D and 
carriage of DRB1*15 did not see any interaction affecting on MS risk [63]. The authors 
did however use the vitamin D levels in adulthood at, or close to, time of diagnosis and 
these may differ to the levels in childhood. 
 
 
4.3 PAPER IV 
The idea behind paper four was presented to me by my colleagues Malin, Katharina 
and Anna who already had an idea around a research question that addressed NAb 
(neutralizing antibody) development in IFN-β  (interferon beta) treated patients. A 
group in Germany had published that NAb development in MS patients treated with 
IFN-β differed with HLA-DRB1 genotype [65-67], and the idea was to study this also 
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within our cohort since we have slightly different outcome measures. The design was 
however not that easy, which we realized quite soon.  
 
The German studies used a different technique to study NAb presence in serum from 
MS patients on IFN-β treatment than what is used in the Swedish NAb registry. Their 
technique detects not only NAbs but also BAbs (binding antibodies) directed to various 
epitopes on the IFN-β molecule that does not necessarily abolish the binding ability of 
IFN-β to its receptor. Thereby, the BAbs do not always interfere with the biological 
function of the protein which is measured by the downstream expression of MxA in 
real time PCR. Their three outcomes were therefore 1) presence of antibodies targeting 
IFN-β, 2) presence of neutralizing ability among those antibodies and 3) the percentage 
of neutralizing ability of the antibodies (Table 4).  
 
With our technique, the first outcome was NAb positivity since we measured MxA 
expression as a first step in the NAb analysis. The next outcome was the presence of 
clinically relevant titers of NAbs defined as the titer necessary to abolish the biological 
activity of IFN-β  in vivo. Our third outcome was the actual titer level and to see if any 
allele group affected the ability of producing high titers. The outcomes of our and the 
German studies are illustrated in figure 4 and summarized in table 4. 
 
 Table 4. Definitions of different outcomes used in the German studies [65-67] and our 
study. 
Outcome German studies  Definition 
All AB  Binding ability of antibody to IFN coated ELISA 
Biologically active antibodies (NAbs)  Enough Abs to reduce MxA expression >50% 
Neutralizing antibody activity  Point estimation of neutralizing ability of antibodies in each sample
Outcome our study  Definition 
Nab  Presence of NAbs (>10 TRU/ml) 
Clinically relevant titers  Enough NAbs to reduce MxA expression ~ 80% (>150 TRU/ml)* 
Titer level of Nabs  Point estimation of NAb titer in each sample 
TRU = Ten fold reduction units, IFN = interferon, AB = antibody, * = as reported in [68]. 
 
The noise of irrelevant binding of BAbs was naturally reduced by the nature of the 
MxA. The choice of analyzing a previously reported relevant cut off for neutralizing 
ability [68], increases the clinical importance of this study. 
 30 
 
Figure 4. Comparison of level of inhibition of biological activities in the outcomes. NAb 
activity spans everything from 0 to 100% neutralizing ability in the German studies, titer level 
in our study spans from 10 TRU/ml to 65,000 TRU/ml. 
 
After a lot of discussions, it was decided that we should analyze all patients that were 
positive for NAbs and the patients that was truly negative. We thereby ignored those 
that had no samples taken within 36 months from beginning of treatment. However, not 
all the patients fulfilling the criteria within the NAb registry were HLA genotyped. 
Since the main question was to determine the effect of HLA genes in development of 
NAbs we reduced the sample population to those patients that were HLA typed, mainly 
patients included in paper I and II in this thesis.  
 
4.3.1 Patient ascertainment biases 
There are three main biases in the patient ascertainment for this study and this type of 
problem is hard to avoid in clinical research. 
1) Patients who more often visit the clinic have a higher probability of being asked 
to donate a sample of blood for research (and thereby being HLA-genotyped). 
They also have a larger set of data points in our registries which increase their 
probability to fulfill the criteria of this study. Why do patients go to the clinic 
often? They might have more symptoms, either due to a more severe disease 
course or due to no effect of the treatment. This inflates the number of patients 
in the NAb registry with a higher probability of NAbs. 
2) The Swedish NAb registry was started in 2003 and NAb tests are taken around 
12 and 24 months after start of treatment. Other samples are taken at other time 
points either as follow up after a positive test, or if there seems to be no effect 
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of the treatment. The patients we defined as negative in the study have all been 
tested at the clinic from 2003 and onwards. Those who have a positive sample 
might have been positive for a long time previous to the test, while older 
patients negative for a long time were excluded due to absence of data points 
within the first 36 months of treatment. Therefore the NAb positive patients are 
older than the NAb negative patients in this study and this could influence the 
ability of producing NAbs. 
3) Between the years 1993 and 1998, Betaferon was the only IFN-β  treatment 
used in the clinic. Later Avonex and Rebif was introduced, but for older 
patients closer to conversion to SPMS, the high dose Betaferon was used to a 
higher degree since it had better effect on relapse inhibition despite more side 
effects. Avonex or Rebif are given to younger patients with a slower 
progression, since these drugs are administered fewer times per week and 
therefore affect daily life less.  Many patients therefore started with Betaferon, 
became NAb positive and experienced no effect of the treatment. When Avonex 
and Rebif were introduced the patients who switched could remain positive for 
NAbs due to cross reactivity from previous Betaferon use [69-71]. This would 
give us a bias of higher probability of positivity connected to older patients who 
used Betaferon when Avonex and Rebif were not used. These patients may be 
registered on another treatment today. 
 
These biases call for somewhat cautious evaluation of the results and a role of potential 
confounding is warranted. The effect of treatment regimen on NAb development has 
previously been studied within the full registry data, showing that Betaferon and Rebif 
induce NAb titers to a larger extent than Avonex [72] which was also seen in our 
sample. However, given the conservative inclusion criteria for the negative group in 
this design, the effect on NAb induction is inflated.  
  
 
4.3.2 Genetic impact on NAb development 
In this study, we could see a weak association between DRB1*15 and NAb 
development which became stronger if correcting for treatment. An increased OR for 
NAb development in Rebif users if positive for DRB1*15 compared to those that were 
DRB1*15 negative was found. This was also shown for titers high enough to diminish 
the effect of the treatment. It would only be logical if an association of a HLA allele to 
antibody development were of class II origin since CD4+ T-cells which recognize 
peptides on HLA class II molecules are excellent activators of antibody producing B-
cells. However, in Betaferon treated patients we saw an increase in odds of NAbs if the 
patients carried the class I allele group HLA-A*02. This result must be verified in 
another cohort because it is based on a test of 42 A*02 positive NAb positive patients 
and only one A*02 positive NAb negative patient that could result from either a 
clinically relevant effect (however difficult to explain) or be a sample bias. 
 
The development of NAbs was also higher if treated with Rebif or Betaferon while 
Avonex does not induce NAbs to the same extent. Would it be wise to put all patients 
on Avonex to start with, and extra beneficial for those who are DRB1*15 positive? This 
 32 
is a very strong conclusion based on a study that is to a certain extent biased and not 
representative for the whole clinic base of patients. That is important to remember. 
 
The German studies identified an association between DRB1*04 and NAbs, and also 
subtyped the DRB1*04 allele group to identify if all alleles were associated with risk. 
DRB1*04:01 and DRB1*04:08 was associated with higher risk while DRB1*04:04 was 
not. In our study we did not see an association between DRB1*04 and NAb 
development and this can be the result of higher frequency of DRB1*04:04 in our 
population. This is something that I would like to study further in this paper. 
   33 
5 FUTURE PERSPECTIVES 
My results from the four studies do add some information to the previously known data 
on HLA in MS susceptibility. We now have further evidence that protection to MS 
does not only involve HLA-A, but also HLA-B probably in combination. We know that 
there do seem to be a month of birth effect in MS even if we could only see it when 
stratifying on DRB1*15, however the link to vitamin D is a bit vague. And lastly there 
seems so be a modulating effect of DRB1*15 on development of NAbs but it does not 
overcome the effect of the treatment regimen themselves.   
  
Since we have some previous clues to what actual role HLA have in MS the hypotheses 
of possible interactions are numerous and need to be studied in detail. Both interactions 
between DRB1 alleles, in-between genes and with environment are important since 
they are all involved in the main hypotheses of MS immunopathogenesis. The immune 
system is built to interact with and respond to stimuli in the surrounding milieu. 
Disease susceptibility might depend on if HLA molecules can bind certain peptides 
more efficiently like in celiac disease [19] or if certain HLA alleles have differential 
expression, thereby presenting different amount of antigens. That would just add 
another level of complexity to the question. DNA methylation of DRB1*15 does not 
seem to affect MS severity [73] but that does not rule out that other haplotypes carry 
important methylation patterns. Perhaps whole blood is not the most appropriate tissue 
to study for functional studies in MS as the methylation pattern for a gene can vary 
from tissue to tissue [74]. CSF derived cells are naturally a more suitable source for this 
type of study, but the amount is limited. It would also be valuable to study one cell type 
at the time since the relative amount of immune cells in blood is different between 
individuals.  
 
The role of genetics on treatment effect is quite interesting since it would enable 
clinicians to evaluate the effectiveness of different treatments in a patient. The other 
way around, that type of information could be used to develop better treatments since it 
is a clue to how the body reacts to the drug. This is however only true if all other 
parameters are held fixed, having the same side effects, same distribution pattern and so 
forth. As each individual is unique there are always those that will react differently to 
the same drug even if we can control for a specific HLA allele group. When 
considering the impact of the genetic effect compared to the drug effect in this study I 
am not convinced that this will be applicable in the clinic, however it might point in 
which direction to go when trying to eliminate the risk of having no effect of the 
treatment. 
 
I think the next step to study the role of HLA in MS is to learn from other autoimmune 
diseases and go back to basic studies of expression, binding and interaction with the T-
cell receptors especially in settings of environmental factors. And perhaps not only 
study DRB1*15, who knows what we will find if we broaden our mind a bit and study 
also the protective alleles like DRB1*01 or DRB1*07 in these settings or the other 
polymorphic genes included in the risk haplotype.  
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One way of getting closer to the role of HLA in MS could be to study if certain amino 
acids or motifs of the HLA molecules are more strongly associated to disease than the 
classic DRB1*15 haplotype. That would indicate an importance of the HLA proteins in 
MS susceptibility. 
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